NEWPORT BEACH, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) — Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 10
th
Annual SVB Leerink Global Healthcare Conference.
|
Event: |
10 th Annual SVB Leerink Global Healthcare Conference |
||
|
Format: |
Fireside Chat & 1×1 Meetings | ||
|
Date: |
Wednesday, February 24, 2021 | ||
|
Time: |
1:00pm – 1:30pm ET | ||
|
Location: |
Evolus Live Fireside Chat |
An audio webcast of Evolus’ fireside chat will be available on the investor relations section of Evolus’ website at
investors.evolus.com
. Replays of the webcasts will be available for 90 days after the date of the presentation.
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau
®
(prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure
™
technology. Jeuveau
®
is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at:
www.evolus.com
.
Jeuveau
®
is a registered trademark of Evolus, Inc.
Hi-Pure
™
is a trademark of Daewoong Pharmaceutical Co, Ltd.
Evolus, Inc. Contacts:
Investor Contact:
Ashwin Agarwal, Evolus, Inc.
Vice President, Finance, Investor Relations & Treasury
Tel: +1-949-284-4559
Email: [email protected]
Media Contact:
Crystal Muilenburg, Evolus, Inc.
Vice President, Corporate Communications & Public Relations
Tel: +1-949-284-4506
Email: [email protected]
